Clinical Trials Logo

Neuromuscular Blockade clinical trials

View clinical trials related to Neuromuscular Blockade.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06102915 Completed - Clinical trials for Coronary Artery Disease

Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

Start date: August 1, 2023
Phase:
Study type: Observational

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

NCT ID: NCT05718934 Completed - Clinical trials for Neuromuscular Blockade

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

SUGANEO
Start date: November 8, 2022
Phase: Phase 4
Study type: Interventional

The aim of this study is to compare the use of a low dose sugammadex and neostigmine combined to glycopyrrolate to reverse a rocuronium induced moderate neuromuscular blockade.

NCT ID: NCT05689957 Completed - Clinical trials for Neuromuscular Blockade

Moderate vs Deep Neuromuscular Block in Lower Pressure Pneumoperitoneum

Start date: December 13, 2020
Phase: N/A
Study type: Interventional

The investigators hypothesized that deep neuromuscular block compare to moderate neuromuscular block would reduce the rate of increasing intraabdominal pressure and operation can be completely done in lower pressure pneumoperitoneum and would improve laparoscopic space by measuring distance from the sacral promontory to the inserted trocar in patients undergoing laparoscopic gynaecological surgery.

NCT ID: NCT05687253 Completed - Surgery Clinical Trials

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Start date: October 25, 2022
Phase: Phase 2
Study type: Interventional

Assessment of Intubation conditions following administration of neuromuscular blocking agents; BX1000 (investigational) or rocuronium (active control).

NCT ID: NCT05474638 Completed - Clinical trials for Neuromuscular Blockade

Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery

Start date: October 25, 2022
Phase: N/A
Study type: Interventional

Two recent pilot studies suggested the potential interest of 100 and 200 Hz tetanic stimulations to detect with mechanomyography (MMG) very low levels of residual neuromuscular blockade (NMB). The Tetanic Fade Ratio (TFR, residual force after 5 seconds / maximal force) measured quantitatively by MMG during tetanic stimulation at 100 or 200 Hz could provide today a more consistent response than the train-of-four (TOF) ratio provided by acceleromyography (AMG) to this search for detection of low levels of residual NMB. This study was designed to evaluate for the first time in anesthetized patients the evolution of NMB spontaneous recovery with 5-second 100 and 200 Hz tetanic stimulations compared to TOF, and to test the hypothesis that a 200 Hz TFR would better and longer detect low levels of residual paralysis than AMG TOF ratio and 100 Hz TFR.

NCT ID: NCT05313100 Completed - Smoking Clinical Trials

Sugammadex and Smoker's Neuromuscular Block

Start date: April 2012
Phase: Phase 4
Study type: Interventional

We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.

NCT ID: NCT05120999 Completed - Clinical trials for Neuromuscular Blockade

Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring

Start date: October 25, 2021
Phase:
Study type: Observational

The purpose of this research is to use 2 devices to compare the difference in the amount of time it takes for each device to register complete muscle relaxation after the muscle relaxing medication is given. The comparison will be made by using electromyographic (EMG), such as TetraGraph, and acceloromyographic (AMG), such as TOFScan, monitors at the time of insertion of breathing tube.

NCT ID: NCT05066035 Completed - Clinical trials for Neuromuscular Blockade

Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

Start date: May 1, 2013
Phase: Phase 4
Study type: Interventional

Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end of the operation. Our goal is to compare the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine to the routine use of reversal medication.

NCT ID: NCT05023343 Completed - Clinical trials for Neuromuscular Blockade

Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

Start date: October 2, 2021
Phase: Phase 4
Study type: Interventional

The aim of this study is to examine whether the administration of the TQL block cause motor block of the lumbar plexus and thereby quadriceps muscle weakness. The investigators hypothesise that the administration of a unilateral TQL block does not cause quadriceps muscle weakness compared to a placebo block.

NCT ID: NCT04996394 Completed - ARDS Clinical Trials

"Effects of Neuromuscular Blocking Agents on End Expiratory Lung Volume During Moderate-severe ARDS"

EIT_CURARO
Start date: December 12, 2019
Phase:
Study type: Observational

This is a monocentric, prospective, observational study that will be conducted in the general ICU of San Gerardo Hospital (Monza, Italy). Study protocol will be started when NMBAs infusion will be stopped for clinical reason until regain of spontaneous breathing activity. Patients will be enrolled at the moment of NMBAs infusion interruption ("baseline" phase). Clinical data will be collected: hemodynamics, ventilation parameters and respiratory mechanics, arterial blood gas analysis, drugs used for sedation and their dosages. An EIT belt will be positioned around the patient's chest when clinical signs of spontaneous breathing activity will be detectable (unstable flow curve on the ventilator, deflection in airway pressure during an expiratory pause). In this phase ("NMBA interruption") same clinical data will be collected as at baseline. Patients will be ventilated in the same ventilation mode as before (Volume Controlled mechanical ventilation), but the inspiratory trigger on the ventilator will be turned on to reduce patient-ventilator asynchronies. When an EIT trace lasting at least 10 minutes will be recorded, an NMBA bolus (as prescribed by the treating physician) will be administered and a continuous infusion will be restarted. Clinical data will be collected again in this phase ("NMBA restart").